MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.semarthrit.2022.152153

Медицинская библиотека · Seminars in arthritis and rheumatism · 2022

Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.

Barroso-García Nuria, Atienza-Mateo Belén, Ferraz-Amaro Iván, Prieto-Peña Diana, Beltrán Emma, Adán Alfredo, Hernández-Garfella Marisa, Martínez-Costa Lucía, Cordero-Coma Miguel, Díaz-Llopis Manuel, Herreras José M, Maíz-Alonso Olga, Torre-Salaberri Ignacio, De Vicente-Delmás Ana, Díaz-Valle David, Atanes-Sandoval Antonio, Francisco Félix, Insua Santos, Sánchez Julio, Almodóvar-González Raquel, Jiménez-Sosa Alejandro, Ruiz-Moreno Oscar, Gandía-Martínez Myriam, Nolla Joan M, Calvo-Río Vanesa, Castañeda Santos, González-Gay Miguel A, Blanco Ricardo

СтатьяОбзорПеревод в очереди

Аннотация

OBJECTIVE

To compare the efficacy of TNF inhibitors (adalimumab (ADA) and infliximab (IFX)) vs tocilizumab (TCZ) in patients with refractory cystoid macular edema (CME) due to Behçet's disease (BD).

METHODS

Multicenter study of patients with BD-associated CME refractory to conventional and/or biological immunosuppressive drugs. From a cohort of 177 patients treated with anti-TNF and 14 patients treated with TCZ, we selected those with CME at baseline. We analyzed the evolution of macular thickness (main outcome), best-corrected visual acuity (BCVA) and intraocular inflammation (Tyndall and vitritis) from baseline up to 4 years in the 3 groups mentioned.

RESULTS

49 patients and 72 eyes with CME were included. ADA was used in 25 patients (40 eyes), IFX in 15 (21 eyes) and TCZ in 9 (11 eyes). No statistically significant baseline differences were observed between the 3 groups except for a lower basal BCVA in TCZ group and a higher basal degree of intraocular inflammation in ADA group. Most patients from all groups had received several conventional immunosuppressive drugs. In addition, most patients in the group of TCZ had also received anti-TNF agents. Biological therapy was used in monotherapy (n=8) or combined with conventional immunosuppressive drugs (n=41). Macular thickness progressively decreased in the 3 groups, with no signs of CME after 1 year of treatment. Similarly, BCVA improvement and inflammatory intraocular remission was achieved in all groups.

CONCLUSION

Refractory CME associated with BD uveitis can be effectively treated either with ADA, IFX or TCZ. Furthermore, TCZ is effective in patients resistant to anti-TNF therapy.

Для цитирования: Barroso-García Nuria, Atienza-Mateo Belén, Ferraz-Amaro Iván, Prieto-Peña Diana, Beltrán Emma, Adán Alfredo, Hernández-Garfella Marisa, Martínez-Costa Lucía, Cordero-Coma Miguel, Díaz-Llopis Manuel, Herreras José M, Maíz-Alonso Olga, Torre-Salaberri Ignacio, De Vicente-Delmás Ana, Díaz-Valle David, Atanes-Sandoval Antonio, Francisco Félix, Insua Santos, Sánchez Julio, Almodóvar-González Raquel, Jiménez-Sosa Alejandro, Ruiz-Moreno Oscar, Gandía-Martínez Myriam, Nolla Joan M, Calvo-Río Vanesa, Castañeda Santos, González-Gay Miguel A, Blanco Ricardo. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.. Seminars in arthritis and rheumatism. 2022. DOI: 10.1016/j.semarthrit.2022.152153.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.